Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mAR-PSMA-PLGA
- Development stage
- Preclinical
- Lead developer
- Seoul National University
- Modality
- Gene Therapies, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
mAR-PSMA-PLGA is an experimental gene therapy candidate developed by researchers at Seoul National University for the treatment of prostate cancer, specifically targeting castration-resistant prostate cancer (CRPC) and enzalutamide-resistant cases. The therapeutic consists of a poly(lactic-co-glycolic acid) (PLGA) nanoparticle that is PEGylated and functionalized with a prostate-specific membrane antigen (PSMA) antibody to ensure targeted delivery to prostate cancer cells. The nanoparticle encapsulates a plasmid vector encoding a non-functioning mutant androgen receptor (mAR) with a 3-base pair deletion in the DNA-binding domain. Upon delivery, the constant overexpression of this non-functional AR competes with endogenous androgen receptor signaling, thereby suppressing tumor cell proliferation and reversing resistance to androgen deprivation therapies like enzalutamide.
- Other names
- mutant androgen receptor-PSMA-PLGA nanoparticlemAR-PSMA-PLGA nanoparticle
02
Targets
PSMA (Prostate-specific membrane antigen)AR (Adrenergic receptors)
Beyond the preview
Go deeper on mAR-PSMA-PLGA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mAR-PSMA-PLGA.